Propel Implant

Breakthrough Treatment Improves Outcomes of Sinus Surgery

Toledo Clinic ENT is among the first in the United States to offer patients with chronic sinusitis an innovative new technology for maintaining the results of sinus surgery.

Chronic sinusitis leads to difficulty breathing, facial pain or headache, and reduced sense of smell and taste – greatly impacting quality of life. The condition is common, affecting 31 million people in the U.S., according to the National Center for Health Statistics.

The PROPEL® mometasone furoate implant was developed to improve quality of life for patients with chronic sinusitis by maintaining the openings created during sinus surgery. Applying principles of coronary drug-eluting stents to sinusitis sufferers, the spring-like implants gradually deliver an advanced steroid with anti-inflammatory properties directly to the sinus lining, then dissolve. The result is improved surgical outcomes, reducing the need for additional surgical procedures and for systemic steroids, which can have serious side effects.

Fact Sheet

“The PROPEL implant offers new hope for chronic sinusitis sufferers,” said Dr. Perry “The goal of sinus surgery is to enlarge the inflamed or obstructed sinus passageways. Three studies have shown that PROPEL maintains the opening created in surgery, translating into significant benefits for patients with chronic sinusitis. After PROPEL, many of my patients have once again been able to enjoy life without the symptoms of chronic sinusitis.”

Clinical Data Summary

The clinical data supporting PROPEL is unique in the field of ENT. Level 1-A clinical evidence has been published proving that use of the product in sinus surgery provides a statistically significant reduction in the need for additional medication and surgical procedures and also reduces post-operative scarring and inflammation that can compromise the benefit of the surgery. Safety and efficacy of the PROPEL mometasone furoate implant has been studied in three prospective clinical trials conducted in the United States. For additional information, visit www.PROPELOPENS.com.